Foghorn Therapeutics (FHTX) Free Cash Flow (2019 - 2026)

Foghorn Therapeutics' Free Cash Flow history runs 8 years deep, the most recent figure standing at -$25.3 million for Q1 2026.

• On a quarterly basis, Free Cash Flow fell 5.29% year-over-year to -$25.3 million in Q1 2026; TTM through Mar 2026 was -$87.4 million, a 8.86% increase from a year earlier, with the FY2025 full-year figure at -$86.1 million, up 15.02% from the prior year.
• Free Cash Flow retreated to -$25.3 million in Q1 2026 per FHTX's latest filing, from -$22.3 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $271.3 million in Q1 2022 and bottomed at -$32.0 million in Q2 2023.
• The 5-year median for Free Cash Flow is -$25.3 million (2026), against an average of -$8.2 million.
• Biggest YoY gain for Free Cash Flow was 1225.39% in 2022; the steepest drop was 294.87% in 2022.
• Year by year, Free Cash Flow stood at -$28.9 million in 2022, then grew by 0.6% to -$28.7 million in 2023, then climbed by 12.92% to -$25.0 million in 2024, then rose by 10.91% to -$22.3 million in 2025, then dropped by 13.45% to -$25.3 million in 2026.
• Per Business Quant, the three latest FHTX Free Cash Flow figures stand at -$25.3 million (Q1 2026), -$22.3 million (Q4 2025), and -$18.9 million (Q3 2025).